Fulcrum Therapeutics (FULC)

• Market cap: $153M
• 1 day: 2.54%
• 5 days: -6.60%
• 1 month: -12.65%
• 3 months: -41.53%
• 6 months: -26.87%
• Year to date: -41.53%
• 1 year: -68.80%
• 5 years: -72.87%
• 10 years: -79.04%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Employees: 45

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

2,399% more call options, than puts

Call options by funds: $5.45M | Put options by funds: $218K

24% more capital invested

Capital invested by funds: $197M [Q3] → $243M (+$46.4M) [Q4]

7.64% more ownership

Funds ownership: 88.31% [Q3] → 95.95% (+7.64%) [Q4]

9% less funds holding

Funds holding: 130 [Q3] → 118 (-12) [Q4]

18% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 40

27% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 33

100% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 0 (-2) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 41% upside
• Avg. target: $4 41% upside
• High target: $4 41% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

HC Wainwright & Co. Andrew Fein 41% 1-year accuracy 57 / 138 met price target

41% upside $4

Neutral Reiterated

26 Feb 2025